Delivery Order SPE2DB20D3103-SPE2DB25FQ4J3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,678.14 for Xyosted 75 mg/0.5 mL auto-injector supplies on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price, non-set-aside delivery order will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector medication with a contract ceiling value of $2,476.04. This firm fixed-price delivery order, which extends through August 29, 2025, represents a pediatric or adult testosterone replacement therapy product to support federal medical supply requirements. The contract was competitively awarded without a set-aside designation and will be...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,375.49. The contract carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. Performance will be executed from the company's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units valued at $1,094.38 with a firm fixed price structure. This non-set-aside contract is classified as a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date for this delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector vials valued at $1,789.66. This is a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and represents a non-competitive award under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its...
- The Defense Logistics Agency awarded a delivery order valued at $3,046.96 to AmerisourceBergen Drug Corp for the supply of Xyosted 50 mg/0.5 ml auto-injector units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and was executed on June 25, 2025, with an ultimate completion date of June 26, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $1,751.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies on September 2, 2025, with completion targeted for September 3, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle active through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector medication valued at $1,127.92. This is a firm fixed price delivery order with an ultimate completion date of August 12, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ4J3Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $3,469.78 by the Defense Logistics Agency (DLA) on September 23, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector medication. This is a firm fixed price, non-set-aside contract with a completion date of September 24, 2025, with performance based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as the prime contract vehicle enabling the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, demonstrates significant capability in meeting federal medical procurement requirements through this award and its broader contract portfolio with DLA. The company's federal contracts consistently involve delivery orders with firm fixed pricing across multiple therapeutic domains, serving critical customers including the Defense Health Agency and the U.S. Coast Guard. This particular delivery order for testosterone replacement therapy represents a routine fulfillment of AmerisourceBergen's extensive responsibilities under its global pharmaceutical support vehicle with the Defense Logistics Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 9/23/25 |